GetTopicDetailResponse(id=7003598934b, topicName=晚期非小細(xì)胞肺癌, introduction=晚期非小細(xì)胞肺癌, content=null, image=null, comments=2, allHits=2039, url=https://h5.medsci.cn/topic?id=59893, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=31363, tagList=[TagDto(tagId=31363, tagName=晚期非小細(xì)胞肺癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2260861, encodeId=d6272260861c5, content=<a href='/topic/show?id=7003598934b' target=_blank style='color:#2F92EE;'>#晚期非小細(xì)胞肺癌#</a> <a href='/topic/show?id=028c1189e9f3' target=_blank style='color:#2F92EE;'>#蘆康沙妥珠單抗#</a>, objectTitle=95%肺癌患者持續(xù)緩解6個(gè)月！中腫張力&方文峰團(tuán)隊(duì)研究登《自然-醫(yī)學(xué)》, objectType=article, longId=872107, objectId=1dbc8e21077d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716269288072_5579292.png, objectUrl=/article/show_article.do?id=1dbc8e21077d, replyNumber=0, likeNumber=35, createdTime=2025-04-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dbc8e21077d, moduleTitle=95%肺癌患者持續(xù)緩解6個(gè)月！中腫張力&方文峰團(tuán)隊(duì)研究登《自然-醫(yī)學(xué)》, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1dbc8e21077d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204857, encodeId=e64b220485e50, content=<a href='/topic/show?id=7003598934b' target=_blank style='color:#2F92EE;'>#晚期非小細(xì)胞肺癌#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫檢查點(diǎn)抑制劑#</a> <a href='/topic/show?id=23fb11449671' target=_blank style='color:#2F92EE;'>#情緒困擾#</a>, objectTitle=Nat. Med | 情緒困擾與晚期非小細(xì)胞肺癌患者免疫檢查點(diǎn)抑制劑治療效果的關(guān)系, objectType=article, longId=825842, objectId=a0f8825842a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240514/1715692987047_6145188.png, objectUrl=/article/show_article.do?id=a0f8825842a4, replyNumber=0, likeNumber=108, createdTime=2024-05-15, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a0f8825842a4, moduleTitle=Nat. Med | 情緒困擾與晚期非小細(xì)胞肺癌患者免疫檢查點(diǎn)抑制劑治療效果的關(guān)系, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a0f8825842a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2162193, encodeId=fcc121621930b, content=癌癥疫苗與化療對(duì)HLA-A2陽(yáng)性<a href='/topic/show?id=7003598934b' target=_blank style='color:#2F92EE;'>#晚期非小細(xì)胞肺癌#</a><a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治療#</a><a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>的隨機(jī)開放標(biāo)簽對(duì)照研究, objectTitle=Ann. Oncol | 癌癥疫苗與化療對(duì)HLA-A2陽(yáng)性晚期非小細(xì)胞肺癌免疫治療耐藥患者的隨機(jī)開放標(biāo)簽對(duì)照研究：ATALANTE-1, objectType=article, longId=795520, objectId=bea5e9552083, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301010/1696948482253_6145188.png, objectUrl=/article/show_article.do?id=bea5e9552083, replyNumber=0, likeNumber=158, createdTime=2023-10-11, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bea5e9552083, moduleTitle=Ann. Oncol | 癌癥疫苗與化療對(duì)HLA-A2陽(yáng)性晚期非小細(xì)胞肺癌免疫治療耐藥患者的隨機(jī)開放標(biāo)簽對(duì)照研究：ATALANTE-1, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bea5e9552083)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1068722, encodeId=060e1068e22c9, content=<a href='/topic/show?id=7003598934b' target=_blank style='color:#2F92EE;'>#晚期非小細(xì)胞肺癌#</a>研究表明，安羅替尼在晚期非小細(xì)胞肺癌患者中耐受性良好且有效。腦轉(zhuǎn)移是接受安羅替尼的NSCLC患者PFS的獨(dú)立預(yù)測(cè)因素。需要進(jìn)一步進(jìn)行更大樣本量和更長(zhǎng)的隨訪期的前瞻性研究，以證實(shí)安羅替尼聯(lián)合免疫治療對(duì)NSCLC患者的臨床益處。, objectTitle=晚期非小細(xì)胞肺癌, objectType=topic, longId=59893, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=119, createdTime=2021-11-09, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
前往app查看評(píng)論內(nèi)容
#晚期非小細(xì)胞肺癌#研究表明，安羅替尼在晚期非小細(xì)胞肺癌患者中耐受性良好且有效。腦轉(zhuǎn)移是接受安羅替尼的NSCLC患者PFS的獨(dú)立預(yù)測(cè)因素。需要進(jìn)一步進(jìn)行更大樣本量和更長(zhǎng)的隨訪期的前瞻性研究，以證實(shí)安羅替尼聯(lián)合免疫治療對(duì)NSCLC患者的臨床益處。
